Literature DB >> 31779510

Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis.

Giulia Graziani1, Georg W Herget2,3, Gabriele Ihorst4, Mara Zeissig5,6, Aristeidis Chaidos7, Holger W Auner7, Justus Duyster1,3, Ralph Wäsch1,3, Monika Engelhardt1,3.   

Abstract

Multiple myeloma (MM) often presents with unspecific symptoms and is challenging to diagnose. We performed this DSMM/EMN-analysis via test-(retro-) and validation (prospective) study to determine the time interval from the onset of first symptoms to the diagnosis of MM. The retrospective and prospective analyses were performed in 101 and 176 patients, respectively. The median time from first symptoms to the MM diagnosis in both cohorts was 4 and 6 months, respectively. Frequencies of MM-related pathologic bone fractures, renal, and infectious complications at diagnosis occurred in 41%, 35%, and 16% of patients, respectively. Our MM-questionnaire determined that 39% of patients were dissatisfied with the diagnostic process. PFS and OS proved insignificantly different with shorter (≤6) and longer (>6 months) latency periods. In conclusion, our in depth studies demonstrate that delays in diagnosis do not decrease PFS or OS, but induce MM-related complications and influence patients' satisfaction with their medical care.

Entities:  

Keywords:  Multiple myeloma; complication avoidance; early diagnosis; health services research; time to diagnosis

Mesh:

Year:  2019        PMID: 31779510     DOI: 10.1080/10428194.2019.1695051

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study.

Authors:  D-Y-L Chang-Chan; R Ríos-Tamayo; M Rodríguez Barranco; D Redondo-Sánchez; Y González; R Marcos-Gragera; M J Sánchez
Journal:  Clin Transl Oncol       Date:  2021-01-12       Impact factor: 3.405

2.  Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures.

Authors:  Monika Engelhardt; Gabriele Ihorst; Martin Schumacher; Michael Rassner; Laura Gengenbach; Mandy Möller; Khalid Shoumariyeh; Jakob Neubauer; Juliane Farthmann; Georg Herget; Ralph Wäsch
Journal:  BMC Cancer       Date:  2021-02-17       Impact factor: 4.430

3.  Potential of microRNA expression profile in predicting renal impairment risk in multiple myeloma patients.

Authors:  Daijin Ren; Yuwen Cai; Gaosi Xu
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.